Litcius/Paper detail

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial

Elias Jabbour, Federico Lussana, Pilar Martínez‐Sánchez, Anna Torrent, J. Rifón, Vaibhav Agrawal, Mar Tormo, Ryan D. Cassaday, Thomas Cluzeau, Françoise Huguet, Cristina Papayannidis, Jesús María Hernández‐Rivas, Anita W. Rijneveld, Shaun Fleming, Vladan Vučinić, Boris Böll, Takayuki Ikezoe, Maher Abdul‐Hay, Mary Lynn Savoie, Andre C. Schuh, Céline Berthon, Stefan Schwartz, Sabina Chiaretti, Junichiro Yuda, Takuya Miyazaki, José González‐Campos, Yuqi Chen, Hansen Wong, Jessica Choudhry, Gerhard Zugmaier, Erin Guest, Paul Gordon, Hagop M. Kantarjian

2025The Lancet Haematology13 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePost-hoc analysisBlinatumomabRefractory (planetary science)Clinical trialInternal medicinePost hocOncologyPediatricsLymphoblastic LeukemiaLeukemiaAstrobiologyPhysicsAcute Lymphoblastic Leukemia researchLymphoma Diagnosis and TreatmentCAR-T cell therapy research
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial | Litcius